Skip to main content
. 2011 Dec 20;11(12):968–974. doi: 10.5812/kowsar.1735143X.789

Table 3. Leukocyte Count (103/μL) in Treated Children.

Treated children, No. Baseline After 12 Wk After 24 Wk End of Treatment
Group I; IFN + RBV (n = 119)
SVR a 62 13.7 ± 1.2 12.1 ± 1.1b 12.1 ± 0.9 c 12.4 ± 1.2 c
Treatment-naïve 53 13.7 ± 1.3 12.2 ± 1.1 12.1 ± 0.9 c 12.6± 1.2
Retherapy 9 13.3 ± 0.8 11.5 ± 1.3 11.6 ± 0.8 11.6 ± 1.1
NR a 57 13.7 ± 1.1 12.1 ± 1.3 a 12.6±1.4 c 13.0±1.2 c
Treatment-naïve 48 13.7 ± 0.9 12.2 ± 1.2 12.6 ± 1.1 c 13.0 ± 1.1
Retherapy 9 13.8 ± 1.6 11.9 ± 1.4 12.2 ± 1.2 12.4 ± 1.5
group II; Treated With Peg-IFN-α-2b + RBV (n = 51)
SVR 24 13.5 ± 1.2 b 11.6 ± 1.1 b, c 11.7 ± 1.1 12.0 ± 1.5
Treatment-naïve 15 13.7 ± 1.3 11.5 ± 1.2 11.8 ± 1.0 12.0 ± 1.6
Retherapy 9 13.2 ± 1.3 11.8 ± 0.9 11.4 ± 1.1 12.0 ± 1.4
NR 27 14.0 ± 1.0 b 12.4 ± 1.6 b, c 12.2 ± 1.5 12.6 ± 1.7
Treatment-naïve 10 13.7 ± 1.1 12.0 ± 1.2 12.6 ± 2.1 12.1 ± 1.4
Retherapy 17 14.2 ± 0.9 12.7 ± 1.8 12.0 ± 1.1 12.9 ± 1.8

a Abbreviations: nR; non-responders, SVR; Sustained virological response

b Statistically significant difference, P < 0.05 (time dependent in one group)

c Statistically significant difference, P < 0.05 (between groups 1 and 2)